MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 129 filers reported holding MERSANA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 297.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,337 | -61.4% | 23,100 | 0.0% | 0.00% | -75.0% |
| Q2 2023 | $75,999 | -20.0% | 23,100 | 0.0% | 0.00% | -20.0% |
| Q1 2023 | $94,941 | -29.9% | 23,100 | 0.0% | 0.01% | -37.5% |
| Q4 2022 | $135,366 | -13.2% | 23,100 | 0.0% | 0.01% | -20.0% |
| Q3 2022 | $156,000 | +45.8% | 23,100 | 0.0% | 0.01% | +66.7% |
| Q2 2022 | $107,000 | +16.3% | 23,100 | 0.0% | 0.01% | +20.0% |
| Q1 2022 | $92,000 | -36.1% | 23,100 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $144,000 | -33.9% | 23,100 | 0.0% | 0.01% | -50.0% |
| Q3 2021 | $218,000 | -30.6% | 23,100 | 0.0% | 0.01% | -37.5% |
| Q2 2021 | $314,000 | -16.0% | 23,100 | 0.0% | 0.02% | -5.9% |
| Q1 2021 | $374,000 | -46.2% | 23,100 | -11.6% | 0.02% | -45.2% |
| Q4 2020 | $695,000 | +221.8% | 26,128 | +125.5% | 0.03% | +158.3% |
| Q3 2020 | $216,000 | – | 11,589 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |